@entity19529 ameliorates @entity633 and @entity8 in the animal model of XXXX .

@entity8 @entity6 @entity2316 @entity657 @entity26 @entity3839 @entity1110 @entity633 @entity19529 @entity35 @entity413 @entity2388
@entity2388 is an endogenous antioxidant and anti-inflammatory substance. The present study was implemented to investigate the protective effect of @entity19529 (EP) against the development and progression of @entity2316 in an in vivo and in vitro model. @entity6 @entity35 were prepared by injecting @entity3839 (65 mg/kg). Those that developed @entity6 after 72 h were treated with EP (40 mg/kg) intraperitoneally. @entity6 @entity35 without @entity2388 treatment and nondiabetic @entity35 were used for control. As an in vitro experiment, @entity35 mesangial cells cultured primarily from @entity35 were treated in high- @entity413 (HG; 50 mM) or normal- @entity413 (NG; 5 mM) conditions and with or without @entity2388 . @entity2388 -treated @entity6 @entity35 exhibited decreased @entity633 and attenuated @entity1110 -dependent reactive @entity26 species generation. Immunohistochemistry showed reduced laminin, type IV collagen, and fibronectin deposition in the glomeruli compared with nontreated @entity6 @entity35 . Parallel changes were shown in tissue mRNA and protein expression levels of @entity657 , laminin, fibronectin, and type IV collagen in the kidney. Concordantly, protective effects were also exhibited in the mesangial cell culture system. These findings suggest that @entity2388 protects against @entity8 via @entity1110 oxidase inhibition. The present study established that activation of @entity1110 oxidase plays a crucial role in @entity6 -induced oxidative stress, @entity8 , and ECM molecule expression. @entity2388 exhibited a renoprotective effect in the progression of experimental @entity2316 . Future research is warranted to investigate the protective mechanism of @entity2388 more specifically in relation to @entity1110 oxidase in @entity2316 .
